Fog horn leg horn video8/12/2023 UM metastasizes in approximately 50% of cases, leading to very poor prognosis. It is diagnosed in about 2,000 adults every year in the United States and occurs most often in lightly pigmented individuals with a median age of 55 years, however, it can occur in all races and at any age. Uveal (intraocular) melanoma is a rare eye cancer that forms from cells that make melanin in the iris, ciliary body, and choroid, and is the most common eye cancer in adults. FHD-286 is being developed for relapsed and/or refractory AML, and the company plans to commence a Phase 1 study, in combination with decitabine or cytarabine, in the third quarter of 2023. In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors. The Company plans to present the full results at a future scientific meeting.įoghorn plans to dose the first patient in a Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML patients in the third quarter of 2023.įHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases, or the catalytic engines of the BAF complex, one of the key regulators within the chromatin regulatory system. The trial evaluated 73 metastatic uveal melanoma patients who had been treated with a median of two prior therapies across nine different cohorts. We plan to initiate dosing the FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023 and continue to invest in our promising pre-clinical programs such as Selective-BRM, CBP, EP300, and ARID1B.”įHD-286 Phase 1 Dose Escalation Study Data in Metastatic Uveal Melanoma In the study, nine patients had stable disease and one patient had a durable partial response,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “However, Foghorn does not plan to pursue this indication on its own. “The clinical data further support the safety and tolerability of FHD-286 and build on the previously disclosed AML/MDS data. At this time, the company does not plan to advance FHD-286 in uveal melanoma. These data reinforce the safety and tolerability profile of FHD-286. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). Foghorn anticipates initiating a FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023ĬAMBRIDGE, Mass., J(GLOBE NEWSWIRE) - Foghorn ® Therapeutics Inc. Foghorn does not plan to advance FHD-286 in uveal melanoma Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response selective, allosteric, oral, small molecule inhibitor of BRG1/BRM Clinical data support safety and tolerability profile of FHD-286, a highly potent,
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |